MDM2 Antibody (SMP14), a monoclonal MDM2 antibody of high quality (also known as HdmX antibody, HDM2 antibody) that can detect the MDM2 protein from mouse, rat, and human. MDM2 Antibody (SMP14), is available in both the non-conjugated anti MDM2 antibody form and multiple conjugated anti MDM2 antibodies forms, including agarose (HRP), PE (FITC) and multiple Alexa Fluor (r) conjugates.
MDM, also known as murine double minute-2, was first identified in a murine transform system. MDM2 functions to bind to p53 and prevent p53-mediated transactivation cotransfected reporter constructions. MDM2 is expressed in high numbers of human sarcomas. You can know more about MDM2 antibodies online via https://www.bosterbio.com/anti-mdm2-antibody-pa1378-1-boster.html.
Tumor cells that express MDM2 more than normal can tolerate high levels p53 expression. These results suggest that MDM2 expression may be one of the mechanisms by which tumorigenesis can be stopped. MDM2 Antibody (SMP14), is an important reagent in cancer research. The most frequently mutated human cancer gene, p53, has been identified.
The expression of p53 causes inhibition of cell growth and prevents cells from progressing from the G1 phase to the S phase of their cell cycle. Importantly, p53 is responsible for the arrest of cells during the G1 phase. This happens after cells are exposed to DNA-damaging substances.
MDM2 is a ubiquitin-ligase for P53. It plays a key role in stabilizing p53. MDM2 can be found on chromosome 12 of the q arm. MDM2's interaction with p300 is enhanced by Akt-mediated Phosphorylation at Ser166 and Ser186. This allows MDM2-mediated degradation and ubiquitination of p53.